Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Theodorescu

Showing results (121-130 of 275) with videos related to

Pageof 28
Sort By:
Nature Reviews. Cancer|December 3, 2020
Advances in bladder cancer biology and therapyLinda Tran, Jin-Fen Xiao, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical applicationCarrie W Rinker-Schaeffer, James P O'Keefe, Danny R Welch, et al.
Neoplasia (New York, N.Y.)|December 21, 2010
RalBP1 is necessary for metastasis of human cancer cell linesZhong Wu, Charles Owens, Nidhi Chandra, et al.
Genes & Development|October 31, 2015
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancersJosh Lewis Stern, Dan Theodorescu, Bert Vogelstein, et al.
BMC Cancer|September 7, 2016
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)Darby Oldenburg, Yuanbin Ru, Benjamin Weinhaus, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 8, 2018
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell LinesTahlita C M Zuiverloon, Florus C de Jong, James C Costello, et al.
The Journal of Clinical Investigation|January 17, 2013
Loss of SPARC in bladder cancer enhances carcinogenesis and progressionNeveen Said, Henry F Frierson, Marta Sanchez-Carbayo, et al.
Cancer Research|May 16, 2012
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancerSteven C Smith, Alexander S Baras, Charles R Owens, et al.
Life Sciences|September 13, 2012
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?Donald E Kohan, John G Cleland, Lewis J Rubin, et al.
Cancer Research|March 12, 2009
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPasesKonstadinos Moissoglu, Kevin S McRoberts, Jeremy A Meier, et al.
Pageof 28

Showing results (121-130 of 275) with videos related to

Sort By:
Pageof 28
Nature Reviews. Cancer|December 3, 2020
Advances in bladder cancer biology and therapyLinda Tran, Jin-Fen Xiao, Neeraj Agarwal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical applicationCarrie W Rinker-Schaeffer, James P O'Keefe, Danny R Welch, et al.
Neoplasia (New York, N.Y.)|December 21, 2010
RalBP1 is necessary for metastasis of human cancer cell linesZhong Wu, Charles Owens, Nidhi Chandra, et al.
Genes & Development|October 31, 2015
Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancersJosh Lewis Stern, Dan Theodorescu, Bert Vogelstein, et al.
BMC Cancer|September 7, 2016
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL)Darby Oldenburg, Yuanbin Ru, Benjamin Weinhaus, et al.
Bladder Cancer (Amsterdam, Netherlands)|May 8, 2018
Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell LinesTahlita C M Zuiverloon, Florus C de Jong, James C Costello, et al.
The Journal of Clinical Investigation|January 17, 2013
Loss of SPARC in bladder cancer enhances carcinogenesis and progressionNeveen Said, Henry F Frierson, Marta Sanchez-Carbayo, et al.
Cancer Research|May 16, 2012
Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancerSteven C Smith, Alexander S Baras, Charles R Owens, et al.
Life Sciences|September 13, 2012
Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?Donald E Kohan, John G Cleland, Lewis J Rubin, et al.
Cancer Research|March 12, 2009
Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPasesKonstadinos Moissoglu, Kevin S McRoberts, Jeremy A Meier, et al.
Pageof 28